pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
enterprise-therapeutics PRESS RELEASE ARCHIVE
Jun 14, 2021
Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
Jun 14, 2021
Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
Oct 7, 2020
Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche
Oct 7, 2020
Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche
Aug 17, 2020
Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002
Feb 10, 2020
Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer
Jan 8, 2020
Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients
Oct 15, 2019
Enterprise Therapeutics Awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator
Apr 12, 2018
Enterprise Therapeutics Raises £29 Million ($41 Million USD) Funding
Apr 5, 2017
Enterprise Therapeutics receives funding from Cystic Fibrosis Trust
Nov 10, 2016
Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising
Oct 17, 2016
Enterprise Therapeutics Appoints Dr John Ford as CEO
